BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1459 related articles for article (PubMed ID: 11459815)

  • 41. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W; Bar-Shavit Z
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms involved in bone resorption.
    Udagawa N
    Biogerontology; 2002; 3(1-2):79-83. PubMed ID: 12014848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation.
    Hayashi T; Kaneda T; Toyama Y; Kumegawa M; Hakeda Y
    J Biol Chem; 2002 Aug; 277(31):27880-6. PubMed ID: 12023971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
    Shin MM; Kim YH; Kim SN; Kim GS; Baek JH
    Exp Mol Med; 2003 Jun; 35(3):167-74. PubMed ID: 12858015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
    Uchiyama S; Yamaguchi M
    Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.
    Saito K; Ohara N; Hotokezaka H; Fukumoto S; Yuasa K; Naito M; Fujiwara T; Nakayama K
    J Biol Chem; 2004 Apr; 279(14):13555-63. PubMed ID: 14729681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival.
    Okamatsu Y; Kim D; Battaglino R; Sasaki H; Späte U; Stashenko P
    J Immunol; 2004 Aug; 173(3):2084-90. PubMed ID: 15265944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RANKL pretreatment plays an important role in the differentiation of pit-forming osteoclasts induced by TNF-α on murine bone marrow macrophages.
    Yamashita Y; Ukai T; Nakamura H; Yoshinaga Y; Kobayashi H; Takamori Y; Noguchi S; Yoshimura A; Hara Y
    Arch Oral Biol; 2015 Sep; 60(9):1273-82. PubMed ID: 26099662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues.
    Sasaki H; Yamamoto H; Tominaga K; Masuda K; Kawai T; Teshima-Kondo S; Matsuno K; Yabe-Nishimura C; Rokutan K
    Free Radic Biol Med; 2009 Jul; 47(2):189-99. PubMed ID: 19409483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.
    Takuma A; Kaneda T; Sato T; Ninomiya S; Kumegawa M; Hakeda Y
    J Biol Chem; 2003 Nov; 278(45):44667-74. PubMed ID: 12944401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.
    Arai F; Miyamoto T; Ohneda O; Inada T; Sudo T; Brasel K; Miyata T; Anderson DM; Suda T
    J Exp Med; 1999 Dec; 190(12):1741-54. PubMed ID: 10601350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro.
    Subramaniam M; Gorny G; Johnsen SA; Monroe DG; Evans GL; Fraser DG; Rickard DJ; Rasmussen K; van Deursen JM; Turner RT; Oursler MJ; Spelsberg TC
    Mol Cell Biol; 2005 Feb; 25(3):1191-9. PubMed ID: 15657444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.
    Enomoto H; Shiojiri S; Hoshi K; Furuichi T; Fukuyama R; Yoshida CA; Kanatani N; Nakamura R; Mizuno A; Zanma A; Yano K; Yasuda H; Higashio K; Takada K; Komori T
    J Biol Chem; 2003 Jun; 278(26):23971-7. PubMed ID: 12697767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.